Bandera Partners Has Increased Its Jamba (JMBA) Holding; Senzar Asset Management Increases Position in Theravance Biopharma (TBPH)

Jamba, Inc. (NASDAQ:JMBA) Logo

Gregory Bylinsky increased its stake in Jamba Inc (JMBA) by 41.48% based on its latest 2018Q1 regulatory filing with the SEC. Bandera Partners Llc bought 124,152 shares as the company’s stock rose 6.81% while stock markets declined. The hedge fund run by Gregory Bylinsky held 423,462 shares of the consumer services company at the end of 2018Q1, valued at $3.63 million, up from 299,310 at the end of the previous reported quarter. Bandera Partners Llc who had been investing in Jamba Inc for a number of months, seems to be bullish on the $148.09M market cap company. It closed at $9.5 lastly. It is down 30.74% since May 31, 2017 and is uptrending. It has outperformed by 18.17% the S&P500.

Senzar Asset Management Llc increased its stake in Theravance Biopharma Inc (TBPH) by 9.35% based on its latest 2018Q1 regulatory filing with the SEC. Senzar Asset Management Llc bought 16,056 shares as the company’s stock declined 17.62% with the market. The hedge fund held 187,856 shares of the health care company at the end of 2018Q1, valued at $4.56M, up from 171,800 at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Theravance Biopharma Inc for a number of months, seems to be bullish on the $1.37 billion market cap company. The stock increased 4.10% or $0.98 during the last trading session, reaching $24.88. About 195,826 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 36.55% since May 31, 2017 and is downtrending. It has underperformed by 49.12% the S&P500.

More important recent Jamba, Inc. (NASDAQ:JMBA) news were published by: Seekingalpha.com which released: “Jamba Juice: Have Things Improved?” on May 17, 2018, also Seekingalpha.com published article titled: “More on Jamba’s FY2017 results”, Prnewswire.com published: “Jamba Juice Celebrates Peoria Grand Opening With Special Offer” on May 11, 2018. More interesting news about Jamba, Inc. (NASDAQ:JMBA) was released by: Businesswire.com and their article: “Jamba, Inc. Announces Expected Receipt of Nasdaq Letter” with publication date: May 18, 2018.

Among 3 analysts covering Jamba (NASDAQ:JMBA), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Jamba had 5 analyst reports since August 26, 2015 according to SRatingsIntel. As per Wednesday, August 26, the company rating was upgraded by TheStreet. The company was downgraded on Tuesday, November 10 by Dougherty & Company. Wedbush reinitiated it with “Neutral” rating and $10 target in Tuesday, November 22 report.

Investors sentiment increased to 1.22 in Q1 2018. Its up 0.28, from 0.94 in 2017Q4. It is positive, as 6 investors sold JMBA shares while 12 reduced holdings. 10 funds opened positions while 12 raised stakes. 11.01 million shares or 12.23% less from 12.55 million shares in 2017Q4 were reported. North Carolina-based Captrust has invested 0% in Jamba, Inc. (NASDAQ:JMBA). Morgan Stanley has invested 0% in Jamba, Inc. (NASDAQ:JMBA). State Street Corporation accumulated 19,724 shares. Millennium Llc reported 62,960 shares stake. Northern Tru holds 0% or 37,635 shares. Dimensional Fund Limited Partnership invested in 167,110 shares. Manufacturers Life Ins The invested 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA). Industries Cap Partners Lc has 1.43M shares for 1.39% of their portfolio. Creative Planning owns 0% invested in Jamba, Inc. (NASDAQ:JMBA) for 13,267 shares. Bnp Paribas Arbitrage holds 0% or 2 shares in its portfolio. Moreover, Kennedy Cap Management has 0.04% invested in Jamba, Inc. (NASDAQ:JMBA). Vanguard Group holds 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA) for 531,726 shares. Geode Capital Management Ltd Liability Com stated it has 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA). Citigroup accumulated 13,857 shares. Invesco Limited invested 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA).

Investors sentiment increased to 1.35 in Q1 2018. Its up 0.04, from 1.31 in 2017Q4. It is positive, as 6 investors sold TBPH shares while 25 reduced holdings. 14 funds opened positions while 28 raised stakes. 35.61 million shares or 1.57% more from 35.06 million shares in 2017Q4 were reported. Baupost Limited Liability Corporation Ma owns 9.31 million shares or 2.18% of their US portfolio. One Trading Limited Partnership invested 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Proshare Ltd has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). The New York-based Ny State Common Retirement Fund has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). D E Shaw & Company accumulated 72,869 shares or 0% of the stock. State Of New Jersey Common Pension Fund D reported 225,459 shares stake. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). Hound Prtn Ltd Llc owns 42,082 shares. Alps Advsrs accumulated 0.01% or 72,564 shares. Voya Mngmt Ltd Liability Company accumulated 18,950 shares. Sei Investments invested in 0% or 8 shares. Qs Invsts holds 0% or 2,500 shares. Comml Bank Of Montreal Can holds 6,210 shares or 0% of its portfolio. Old West Mngmt Limited Liability has 1.53% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). Moreover, Deutsche Bancorp Ag has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 84,661 shares.

Among 8 analysts covering Theravance Biopharma (NASDAQ:TBPH), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Theravance Biopharma had 23 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, February 27 by Cantor Fitzgerald. Needham initiated the shares of TBPH in report on Wednesday, December 21 with “Buy” rating. As per Wednesday, November 8, the company rating was maintained by Needham. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, November 7. The rating was initiated by Evercore with “Buy” on Monday, August 29. Cantor Fitzgerald maintained it with “Buy” rating and $5500 target in Tuesday, May 8 report. The rating was maintained by Needham with “Buy” on Friday, September 15. The rating was initiated by Leerink Swann on Thursday, May 12 with “Outperform”. As per Monday, June 20, the company rating was initiated by Guggenheim. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Needham on Wednesday, August 2.

Senzar Asset Management Llc, which manages about $442.00 million and $316.94 million US Long portfolio, decreased its stake in Mylan N V (NASDAQ:MYL) by 112,680 shares to 493,820 shares, valued at $20.33M in 2018Q1, according to the filing. It also reduced its holding in Cvs Health Corp (NYSE:CVS) by 194,670 shares in the quarter, leaving it with 120,830 shares, and cut its stake in Novartis A G (NYSE:NVS).

More news for Theravance Biopharma, Inc. (NASDAQ:TBPH) were recently published by: Seekingalpha.com, which released: “Theravance Biopharma’s (TBPH) CEO Rick Winningham on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. Benzinga.com‘s article titled: “Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching” and published on May 19, 2018 is yet another important article.

Jamba, Inc. (NASDAQ:JMBA) Institutional Positions Chart